孟鲁司特治疗咳嗽变异性哮喘的临床疗效观察

目的探讨孟鲁司特纳治疗咳嗽变异性哮喘(CVA)的临床效果。方法选择2012年2月~2013年2月来我院就诊的CVA患者76例,随机分为观察组和对照组,每组38例,两组患者均予以沙美特罗/醋氟替卡松吸入,1吸/次,2次/d,观察组加用孟鲁司特咀嚼片10 mg,1次/d,口服,连用3个月。观察两组治疗期间肺功能和日夜间症状评分变化,并进行临床疗效和不良反应观察。结果治疗3个月后,两组FEV1%、PEF%和日夜间症状评分均有明显改善(P<0.05或P<0.01),且观察组改善幅度比对照组更明显(P<0.05);观察组患者的临床总有效率为94.73%,比对照组患者的76.32%明显上升(P<0.05);观察组和对照组治疗过程中分别出现不良反应3例(7.89%)和5例(13.16%),两组药物不良反应发生率比较无明显统计学差异(P>0.05)。结论孟鲁司特钠对改善CVA患者的肺功能和临床症状有明显的效果,且具有较好的疗效及安全性。

Observation on the clinical curative effect of montelukast in the treatment of cough variant asthma

Objective To investigate the clinical curative effect of montelukast in the treatment of cough variant asthma （CVA）. Methods Atotal of 76 patients with CVA were selected from February 2012 to February 2013 in our hospital, and randomly divided into the observation group and the control group, each of 38 cases. The patients in the two groups were given salmeterol/flutieasone propionate inhalation, 1 suction every time, 2 times a day, and on this basis the patients in the observation group were taken orally 10 mg montelukast chewable tablets, once a day, even for 3 months. The pulmonary function and day and night symptom score changes of two groups were observed during the treatment, and the clinical curative effect and adverse reactions were also observed. Results After 3 months of treat- ment, the FEVI%, PEF% and day and night symptom scores of two groups were significantly improved （P〈0.05 or P〈 0.01 ）, and which in the observation group were improved more significantly compared with the control group（P〈O.05） ; the clinical total efficient rate of the observation group （94.73%） was significantly higher than that of the control group （76.32%）,P〈0.05; there were 3 cases （7.89%） happened adverse reactions in the observation group and 5 cases （13.16%） happened adverse reactions in the control group during the treatment, the difference was not significant in the incidence of adverse reactions between the two groups（P〉0.05）. Conclusion Montelukast has obvious effect on the improvement of pulmonary function and clinical symptoms in patients with CVA, and has better curative effects and safety.